AbbVie Gets Tariff Relief, Pledges $100 Billion, Lower Prices For Key Medicines
I'm PortAI, I can summarize articles.
AbbVie Inc. has entered a voluntary agreement with the Trump administration to lower drug prices and invest $100 billion in U.S. research and manufacturing over the next decade. The deal includes tariff relief and aims to enhance access to medications like Humira and Synthroid. Additionally, AbbVie has secured exclusive rights to develop RC148 for cancer treatment and plans to acquire a manufacturing facility in Arizona, creating 200 jobs and investing over $175 million. AbbVie shares were down 0.09% to $219.85 in premarket trading.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments